Combining genomic profiling with surgery to assess endometrial cancer spread
Tests whether gene profiling plus surgical checks can guide endometrial cancer staging in adults.
Plain-language title generated from the registry record
Registry title: Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment
Key facts
- Where
- Leuven, BelgiumSee the site
Where in Belgium
- UZ Gasthuisberg, Katholieke Universiteit LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Gasthuisberg
- Trial code
- NCT06354738
- Record updated
- 17 April 2024
- Original description
EUGENIE is a prospective multicentre interventional study, focused on improving endometrial cancer (EC) assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment. The investigators aim to correlate EC stage to each of the molecular subgroups of disease and thereby guide surgical treatment and staging of EC by determining the association between molecular classification and disease stage and evaluating if and how disease stage in each of the molecular subgroups associates with prognosis.Read full original descriptionShow less
Improving Endometrial Cancer Assessment by Combining the New techniqUe of GENomic Profiling With Surgical Extra uterIne disEase Assessment
EUGENIE is a prospective multicentre interventional study, focused on improving endometrial cancer (EC) assessment by combining the new technique of genomic profiling with surgical extra uterine disease assessment. The investigators aim to correlate EC stage to each of the molecular subgroups of disease and thereby guide surgical treatment and staging of EC by determining the association between molecular classification and disease stage and evaluating if and how disease stage in each of the molecular subgroups associates with prognosis.
Inclusion: Voluntary written informed consent of the participant or their legally authorized representative has been obtained before any screening procedures; Women ≥ 18 years; First diagnosis of EC, all disease stages and all histo-types.
Exclusion: Participant has a history of pelvic or para-aortic lymph node dissection or sampling, previous pelvic (and/or para-aortic) radiotherapy, previous neoadjuvant chemotherapy; Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Study; Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol.